Novo Nordisk Shares Tumble as Long-Term Revenue Targets Disappoint

Note: This section contains information in English only.
Source: Dukascopy Bank SA
Shares in Novo Nordisk plunged nearly 8% to close at 260 Danish kroner on Monday, hitting their lowest level since April after the Danish drugmaker's capital markets day presentation failed to reassure investors over its mid-term growth outlook. Despite showcasing positive Phase 3 trial data for its next-generation obesity and diabetes treatment Cagrisema, which achieved greater weight loss than Eli Lilly's Zepbound, investors reacted negatively to conservative 2030 operating margin guidance and a lack of granular turnaround plans as the company faces impending patent expiries for Ozempic and Wegovy.



Actual Topics

Per scoprire di più sulla piattaforma di Dukascopy Bank per Forex/CFD, sul SWFX ed altre informazioni relative al trading,
la preghiamo di contattarci o richiedere di essere contattato (callback request)
For further information regarding potential cooperation,
please call us or make callback request.
To learn more about Dukascopy Bank Binary Options / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
Per scoprire di più sulla piattaforma di Dukascopy Bank per Forex/CFD, sul SWFX ed altre informazioni relative al trading,
la preghiamo di contattarci o richiedere di essere contattato (callback request).
To learn more about Crypto Trading / CFD / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
To learn more about Business Introducer and other trading related information,
please call us or make callback request.
For further information regarding potential cooperation,
please call us or make callback request.